Aclaris Therapeutics (ACRS) Other Non-Current Liabilities (2016 - 2026)

Aclaris Therapeutics' Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $11.0 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 155.34% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (up 155.34% YoY), while the FY2025 annual figure was $11.0 million, up 26.44% from the prior year.
• Other Non-Current Liabilities was $11.0 million for Q1 2026 at Aclaris Therapeutics, roughly flat from $11.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $33.1 million in Q4 2022 to a low of $1.6 million in Q3 2022.
• Historically, Other Non-Current Liabilities has averaged $15.1 million across 5 years, with a median of $10.5 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities soared 1884.13% in 2023, then sank 92.31% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $33.1 million in 2022, then slumped by 81.27% to $6.2 million in 2023, then jumped by 40.32% to $8.7 million in 2024, then increased by 26.44% to $11.0 million in 2025, then changed by 0.0% to $11.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $11.0 million (Q1 2026), $11.0 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.